Probiotics and Allergic Diseases — Usefulness of Animal Models — From Strains Selection to Mechanistic Studies by Neau, Elodie et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 6
Probiotics and Allergic Diseases — Usefulness of Animal
Models — From Strains Selection to Mechanistic Studies
Elodie Neau, Marie-José Butel and
Anne-Judith Waligora-Dupriet
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/59486
1. Introduction
The prevalence of allergies has dramatically and rapidly increased over the past decades in
areas with a “westernized” or “industrialized” lifestyle. This increase and the dichotomy in
the rate of allergic disease between industrialized and developing countries are two lines of
evidence suggesting that environmental changes are a major factor in the development of
allergies. There is mounting evidence that the microbiota is a key environmental factor that
influences oral tolerance. Alterations in the sequential establishment of gut microbiota
observed in western countries could therefore be responsible for a T-helper balance deviation
toward a Th2 profile, a major factor in the rise of allergic diseases. Likewise treatment with
broad spectrum antibiotics in infancy leading to microbiota alterations and dysbiosis, is
associated with increased susceptibility to allergy [1]. Indeed recent epidemiological studies
have linked factors influencing microbiota establishment and risk of allergy [2,3]. Hence,
increasing evidences suggest that the composition of the microbiota influences intestinal
barrier functions [4,5] and both local [6] and systemic immune responses [7]. A specific
signature of the microbiota has been associated with allergy sensitivity [8-10]. This hypothesis
has been confirmed by studies using mice models which have shown that the gut microbiota
is likely to play a role in the development of oral tolerance. We and other have shown that the
lack of gut microbiota in germ free mice is associated with the development of Th2 and IgE
responses to dietary antigens [11,12]. The specific gut microbiota observed in mice with food
allergy by Noval-Rivas et al was able of transmitting disease susceptibility to naive germ-free
recipients [9]. In humans, several studies highlighted differences in the composition of
bacterial communities in the feces of subject with or without allergic diseases; however,
available epidemiological studies remain controversial [13]. Numerous studies support that a
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low diversity of the gut microbiota in infancy is important, more than the prevalence of specific
bacterial taxa but this low diversity can also be attributed to specific bacterial group, such as
Bacteroidetes and Proteobacteria [14-17]. Interestingly, Ling et al described distinct alterations of
the gut microbiota in IgE and non-IgE mediated food allergy [18]. Despite discrepancies
between clinical studies, the likely relationship between the intestinal microbiota and allergy
assess the usefulness of modulation of the gut microbiota that may help prevent and manage
allergic diseases. This notion supports the use of probiotics, prebiotics and symbiotics.
If present results of clinical trials do not allow concluding unambiguously in favor of probi‐
otics, studies have shown the benefits of this approach, justifying further research in this
direction [13,19-21]. Recent reviews reported studies showing the beneficial effects in the
prevention of atopic dermatitis [19-21]. Prevention of respiratory allergies also seems possible
[21]. Differences between studies are most likely due to differences in the populations studied
- in terms of type of allergy, evolutionary stage of the disease, environment, genetic back‐
ground - but also to the various probiotic used in terms of strain, dose, duration and time of
administration in relation to the development of allergy, and finally the follow-up period [13,
19]. The combined prenatal and postnatal administration of probiotics appears more effective
[21]. However, the conflicting results reported today do not allow the recommendation of the
use of probiotics in prevention of allergy by expert committees. Despite the promising results
on prevention and treatment of allergic diseases by various strains, EFSA did not delivered
favorable opinions on requests. Progress in our basic knowledge of probiotic strains, in strain
selection, and in understanding their mechanisms of action is needed to give credibility to the
health claims made for probiotics and especially for the design of efficacious therapeutic
agents. For these reasons, animal models constitute unavoidable tools for biomedical research.
They are used for their potential to mimic the human disease process, and allow better
understanding of key events of allergic disease development.
2. Animal models of food allergy, asthma and atopic dermatitis
In this chapter, only animal models that have been used to characterize the impact of probiotics
on allergy will be described.
The impact of probiotics on allergy – including food allergy, asthma and atopic dermatitis –
was mainly studied on small laboratory animals (mice and rats), but domestic animals, as dogs
and piglets, were also used. It is important to carefully choose animal model because it can
deeply affect the study. Indeed, genetic predispositions condition IgE responsiveness [22].
2.1. Rodent models
2.1.1. Mice model
Mice are the first model organism because of its easy reproduction and its low cost of main‐
tenance. This model does not completely mirror the human but it shares with him similar
mechanisms of immune regulation, notably in T cell polarization [23]. These animals have the
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capacity to produce IgE and IgG1 antibodies, and, depending on their genetic background,
strains can be divided into high or low IgE responders [22]. There are also differences in their
ability to produce Th1 and Th2 cytokines.
Murine models of food allergy and asthma have been investigated in several strains, including
BALB/c, C57BL/6 and C3H/HeJ. BALB/c strain is the most commonly used in models of
experimental induced allergy. Indeed, BALB/c mice develop a strong Th2 response following
sensitization and challenge with an allergen, with higher levels of allergen-specific IgE. It can
be explained by a genetic predisposition towards the development of Th2 cells, implicate in
allergy process [24]. This bias is caused by the loss of functional IL-12 receptor which leads to
promote the generation of IL-4-producing cells. Indeed, IL-12 favors the generation of Th1
effector cells which antagonize the effects of IL-4 [25]. Many authors have succeeded to
sensitize BALB/c mice with different allergens, such as ovalbumin (OVA) [26,27], ovomucoid
[27] and β-lactoglobulin [28]. However, according to protocols, teams have obtained conflict‐
ing results. For instance, Morafo et al have demonstrated that BALB/c mice failed to produce
cow’s milk-specific IgE and did not reproduce symptoms after cow’s milk challenge [29].
C57BL/6 mice are intermediate IgE responders [22] and have been used successfully in allergen
challenge studies [30-32]. C57BL/6 strain has the advantage of being stable and having its
genome entirely sequenced. Moreover, the most available knock-out strains mice are created
on C57BL/6 genetic background.
C3H/HeJ strain is also used [33-35]. It has a mutation in the gene tlr4 which recognize LPS.
This loss of function leads to a higher susceptibility to allergy, with a skewing of the cytokine
response to a Th2 phenotype and an aggravated anaphylactic reaction [36,37]. C3H/HeN strain,
which don’t have this mutation, is also used to obtain an anaphylactic response [11].
One study has compared these three mice strains in a model of asthma [38]. After immuniza‐
tions to OVA/alum, BALB/c strain develops an α-actin smooth muscle hyperplasia and an
airway responsiveness which was more important than in C57BL/6 and C3H/HeJ. These results
have been confirmed by Van Hove et al. [39]. The choice of the murine strain is therefore of
great importance, and must be determined in accordance with objectives. Hence, in food
allergy, BALB/c and C3H/HeJ strains are more relevant to study sensitization with a high IgE
response and anaphylaxis, respectively [29].
Strain NC/Nga, firstly developed by Matsuda et  al  in 1997,  is  widely used in models of
atopic dermatitis (AD) [40]. Inbred NC/Nga can develop skin lesion similar clinically (on
face, neck, ears, nose and dorsal skin) and histologically (with an increase of the number
of mast cells and CD4+T cells, and infiltration of numerous eosinophils) to human. IgE levels
increase in association with clinical severity. These symptoms and signs appear when the
mice  are  raised  under  conventional  conditions,  and  not  under  specific  pathogen-free
conditions, environmental factors provoking AD-like signs [41]. BALB/c strain has also been
used for this application [42].
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2.1.2. Rat model
The rat is another small animal model to examine food allergy, but it is few implemented
[43-45]. Due to the size of this species, it is possible to monitor within individual animals the
kinetics of specific serum antibody responses. They have the capacity to produce IgE and IgG2a
antibodies [46]. The Brown Norway strain is a suitable model with a high-IgE response after
oral sensitization [47,48]. However, Dearman et al [49] have showed that the ability of this
strain to mount IgE responses is somewhat variable and subject to a number of influences
including environmental conditions and/or sub-clinical infection. Sprague-Dawley strain has
also been used to test the impact of probiotic supplementation [44].
2.2. Large animal models
Swine and dogs are an example of large animal models that have been investigated for
allergy. They are less commonly used because they are most expensive than rodents and
their housing is uneasy. However, in many aspects, closer similarities exist between these
large animal species and humans. First, dog’s gut anatomy and physiology and nutrition‐
al requirements are similar to humans [50]. Second, atopic dogs share many allergies with
human.  Indeed,  it  develops  spontaneously  allergic  reaction to  dust  mites  and foods for
example, with an incidence of 10% [51]. In this way, dogs present frequently IgE-mediat‐
ed food hypersensitivity,  with clinical  symptoms comparable to those of  human includ‐
ing gastrointestinal and dermatologic reactions. Of this fact, this model can be utilized for
mimicking and characterizing mechanisms involved in the development of food allergies
in children. To the best of our knowledge, up to now, the impact of probiotics has been
only study on atopic dermatitis [52,53].
Only two teams used swine model within the framework of food allergy [54] and asthma [55].
Swine presents a number of important advantages for study allergy. Indeed, they have a
similarity with young children in terms of size, organ development, intestinal physiology,
whether anatomically or histologically, mucosal immunity and disease progression [56]. They
are able to produce IgG and IgE [51].
3. Protocols of allergic sensitization
Multiple methods are used to induce allergy in animal models. Differences between protocols
consist of the nature and dose of the allergen, and the strategy used to sensitize the animal
prior to challenge (route of exposure and use or not of an adjuvant). The number of sensitiza‐
tions is also extremely variable from one study to another, between 1 and 4 per week, during
1 from 8 weeks, according to the model, the use or not of an adjuvant, and the route of exposure
(Tables 1 to 3).
3.1. Allergens
Many allergens are used to sensitize the different animal species. Ovalbumin (OVA), the main
protein found in egg white, is used in more than 50% of publications on probiotic and allergy.
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Other major allergens are peanut extract in food allergy [30,35,43,57], birch pollen from Betula
verrucosa (Bet v 1) [58-60] and house dust mite Dermatophagoides pteronyssinus (Der p) [32,61,62]
in asthma. The capacity to induce the immune system to produce IgE antibodies, elicit allergic
symptoms, and bind to allergen-specific IgE depend of allergen [63]. For example, by oral
route, the allergenic potential of peanut extract is far higher than the one of cow’s milk [63],
and egg, Brazil nut and spinach [64]. The different allergens induce different types of antibody
isotype patterns, whether it be IgG1, IgG2a, IgE and IgA. The allergenic potential of these
molecules depends on the size and physicochemical properties of the protein, the glycosylation
status, the biologic and enzymatic activities and the way in which the protein is processed and
presented to the immune system [64]. Moreover, all mice strains are not susceptible to the same
allergens. For example, BALB/c genetic background is completely resistant to peanut-induced
anaphylaxis unlike C3H strain [37]. Experimental and clinical data indicate a difference in
gender susceptibility to allergic inflammation [65,66]. These differences appear to vary with
the route of administration used (see 3.2).
The dose of allergen and its frequency of administration are also important parameters in the
magnitude of the immune response. Kroghsbo et al [27] have orally immunized BALB/c mice
with a low (0.5 mg) or a high (5 mg) dose of OVA. Results revealed that the OVA dose had no
impact on the production of IgG1 and IgA, but had an impact on production of IgG2a and IgE,
with a higher level obtained with the higher dose of allergen. Nevertheless, the allergen dose
administered should not be too high. Indeed, a high-dose of allergen can be associated with
an induction of tolerance, while low-dose is known to induce sensitization [51,67]. In addition
to the dose, the frequency of antigen exposure plays also a role. Nelde et al have showed that,
after intraperitoneal (IP) sensitization of BALB/c mice, IgE synthesis was best induced by
increasing the frequency of OVA application with low-dose than with few exposures with high
doses [68]. The magnitude of the sensitization therefore depends on the type and the dose of
the used allergen, but also on the route of administration (see below).
3.2. Route of exposure
The route by which antigen is administered has its advantages and disadvantages, and affects
both the magnitude and the type of response obtained. It must be chosen depending on the
purpose of the study. The route of delivery to animals should closely look like about the
projected route of administration to humans. The most common routes for allergen adminis‐
tration are oral, IP and epicutaneous (EC) routes. Intra-nasal (IN) - for administration of
pneumallergen in model of asthma [69], intra-tracheal (IT) [55], and subcutaneous routes (SC)
[55,59,60,62,70,71] are more rarely employed.
3.2.1. Oral route
To model food allergy, antigen administration via the gastrointestinal tract – in other words,
by gavage (IG) – provides clear ties to the human condition, and it is thus very relevant for
exposure to food antigens. Additionally, it has the advantage of being economical, convenient,
and relatively safe. Oral route also allows testing different allergens to evaluate their allergenic
potential [64]. Oral immunization does not discriminate between males versus females, with
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no differences in their level of Th1 (i.e. IgG2a) or Th2 -associated (i.e. IgE and IgG1) antibodies
[65]. This route can be used for sensitization studies [30,33-35,43-45,72-75] but also for tolerance
studies [76-78]. Consequently, this route is principally used to study the impact of probiotics
on food allergy.
3.2.2. Intraperitoneal route
The intraperitoneal administration is a common technique in laboratory rodents. It can be used
to administer large volumes of fluid safely, unlike oral route which only tolerate low volumes
[79]. The pharmacokinetic of substances administered by this route is closed to those seen after
oral administration, with a passage by the liver. Special care must be taken regarding the
injected substances which should be sterile, isotonic and nonirritating. There are differences
in sensitization according to the gender when this route is applied. Bonnegarde-Bernard et al
have therefore showed that female mice C57BL/6 sensitized by intraperitoneal route develop
higher level of allergen-specific IgE, IgG2a and IgA than males [65]. This route is used in
experimental murine models of food allergy and asthma, in sensitization or tolerance induction
studies [80-83].
3.2.3. Epicutaneous route
Some substances can also be administered directly to the skin surface (epicutaneous admin‐
istration) for a topical affect. The allergen is captured by skin dendritic cells that migrate to the
afferent lymph nodes and activate immune responses and allergen-specific cytokine produc‐
tion [84]. Several studies have demonstrated that this route allows to sensitize to various
antigens, in the absence of adjuvant [85], with a strong Th2 response [86,87]. For that, they
utilized occlusive dressings and/or prolonged exposure to the antigen. The extent of absorption
of substances through the skin and into the systemic circulation depends on many parameters,
as for example the surface area of application, the integrity of the skin and the contact time [79].
Contrary to the oral route, the epicutaneous administration is inadequate to discriminate the
allergenic potential of proteins [64]. This route is very employed in atopic dermatitis model
[52,53,66,88-95].
3.2.4. Comparison of routes of exposure
Several publications have compared the impact of these different routes of administration on
sensitization. Animals can be sensitized to many allergens, but in an adjuvant-dependent
manner, whatever the route practiced (IP, SC, IG, EC, and IN), with a significant production
of allergen-specific IgE, IgG1 and IgG2a [49,64,85]. The maximal level of these immunologic
markers is attained via the cutaneous route [85]. A mucosal administration (i.e. IG, SC or IN
administrations) was shown to develop a robust allergen-specific IgA response by contrast
with a cutaneous exposure [85]. The intraperitoneal route allowed a stronger IgE and IgG
response compared with that obtained by oral route [49], but this response was weaker than
the one observed with intranasal and epicutaneous allergen application [68]. Contrary to the
oral route, intraperitoneal and epicutaneous administrations did not allow the induction of
oral tolerance [87].
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3.3. The use of adjuvant
Most proteins are poorly immunogenic or non-immunogenic when administered on their own.
To increase the immune response and thus sensitize animals, the majority of experimental
studies utilize an adjuvant. The latter leads to a Th2 skewing, and abrogates the establishment
of oral tolerance [96, 97]. There are exogenous Th2 adjuvants as glycans, endogenous adjuvants
as thymic stromal lymphopoietin (TSLP) and experimental adjuvants as cholera toxin,
aluminum hydroxide and enterotoxin B from Staphylococcus aureus.
3.3.1. Cholera toxin
Cholera toxin (CT) is secreted by the bacterium Vibrio cholerae, which is responsible for aqueous
diarrhea. The major effect of CT is to promote the uptake of antigen by antigen-presenting cells
and to facilitate the presentation of antigen to T cells by favoring the intestinal permeability.
Indeed, it induces in vivo the maturation and the migration of gastrointestinal dendritic cells
(DCs) from the lamina propria to the mesenteric lymph nodes where they present antigen to
naive T cells. CT also enhances the migration from the subepithelial dome region of Peyer’s
patches to the interfollicular T-cell areas. This maturation of DCs also includes the up-
regulation of the co-stimulatory molecules OX40L and TIM-4, known to facilitate differentia‐
tion of responder T cells into Th2 cells. The neutralization of these two molecules has been
shown to abrogate Th2 skewing in the gastrointestinal tract [96, 98].
3.3.2. Aluminum hydroxide
Aluminum hydroxide (alum) rarely induces cellular immune responses. However, it slows
down the rate of release of the antigen and in this way increases the duration of antigen
interaction with the immune system. It also promotes macrophage uptake. Therefore, it
enhances the immune response against the antigen [97,99].
3.3.3. Enterotoxin B from Staphylococcus aureus
The enterotoxin B (SEB) is produced by Staphylococcus aureus in a variety of environments,
including food substrates [97]. It causes severe diarrhea, nausea and intestinal cramping often
starting within a few hours of ingestion. In the same way as the cholera toxin, the SEB induces
the up-regulation of co-stimulatory molecules TIM-4, but also CD80 and CD86, which
promotes the Th2 skewing.
3.3.4. Impact of dose of adjuvant
Few studies have focused on the impact of dose adjuvant on sensitization. Kroghsbo et al have
tested three different CT doses (0.1, 1 or 10 µg) on BALB/c mice, sensitized to ovomucoid or
ovalbumin [27]. They have observed a clear dose-dependent response on antibody induction,
with the strongest response at the highest CT dose for any of the tested antibody isotypes (IgG1,
IgG2a, IgE, and IgA). They were able to determine a threshold value (between 0.1 and 1 µg)
for the lowest CT dose needed for sensitization. A weak dose of CT (0.1 µg) leads to initiation
of IgG1 production. To observe an IgE production, a higher dose of CT (10 µg) is necessary.
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4. Probiotic administration
Animal models can be used to select probiotic strains which can prevent or manage allergy,
and to study their mechanism of action. Indeed, these animal models can be discriminant. For
instance, if number of studies showed a positive impact of probiotic supplementation in their
models of allergy (Tables 4 to 6), Meijerink et al showed a strain specific effect in a peanut
allergy model [57]. Lee et al studied the protective impact on OVA sensitization of four strains
of Lactobacillus [100]. None of them induced a change in IgE levels. Moreover, one of them led
to an increase in allergic response. Likewise, de Jonge et al have found similar levels of IgG1
and IgG2a in Brown Norway rats sensitized to peanut extract, receiving or not a strain of L.
casei Shirota by gavage [43]. A lack of benefit of supplementation was also observed in three
models of asthma [62,70,71,101]. Sometimes, an improvement of symptoms, with a decrease
of clinical signs after oral challenge, but without correlation with a decrease in markers of
sensitization can be also observed [54,58,59].
4.1. Evaluation of beneficial effect of probiotic
The beneficial effect of probiotic supplementation is evaluated according to the model used.
4.1.1. Models of anaphylaxis
In models of anaphylaxis, clinical markers are analyzed after challenge by allergen, according
to a scale score based on observed clinical symptoms (number of itches, mobility during the
experiment, swelling of eyes and/or noise, aspect of hair, and body temperature). Thang et al
and Schouten et al have scored symptoms of systemic anaphylaxis as follows: 0=no symptoms;
1=pilar erecti, scratching and rubbing around the nose and head; 2=pilar erecti, reduced
activity; 3=activity after prodding and lowered body temperature; 4=no activity after prodding,
labored respiration, and lowered body temperature; 5=death [28,74]. There are other models
of anaphylaxis, in particular murine models of intestinal anaphylaxis induced by OVA. Food
allergy symptoms are then scored by the criteria of diarrhea and rectal temperature [102,103].
However, this model has not been used yet to evaluate the impact of probiotic.
4.1.2. Models of asthma
In models of asthma, there is no scale of scores. The impact of probiotic is estimated by the
determination of the cellular composition of bronchoalveolar fluid (total cell count and
proportion of each cell type – lymphocytes, neutrophils, eosinophils and monocytes), the
evaluation of number of infiltrated inflammatory cells in lung, and by the measurement of
bronchial hyperresponsiveness [70,81,104].
4.1.3. Models of atopic dermatitis
As in models of food allergy, a scale of scores can be used in models of atopic dermatitis.
Matsuda et al have estimated clinical skin condition after sensitizations as follows: 0=none,
1=mild, 2=moderate, 3=severe, for each of these symptoms: itch, erythema/hemorrhage,
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edema, excoriation/erosion and scaling/dryness [105]. The frequency and the duration of
scratching, the numbers of infiltrated cells and the epidermal/auricular thickening can be also
measured [88,90,105].
The limit of all these evaluations lies in its subjectivity despite a blind evaluation system. This
subjectivity results in a problem of reproducibility of the method. An analysis of biological
markers of allergic reaction, i.e. the dosage in plasma of mast cell protease-1 (MCP-1) and/or
histamine release during mast cell degranulation, provides less subjective data than clinical
score [30,34,35]. These models also allow evaluating sensitization through dosage of allergen-
specific and total IgE, IgG1 and IgG2a [60,92,100].
4.2. Route and dose of probiotic supplementation
The dose of probiotic is often comprised between 106 and 109 CFU. When the dose of probiotic
is tested, the highest dose shows, most of the time, better results [35,62,89,94,106]. Jan et al have
tested three increasing doses of Lactobacillus gasseri (1, 2 and 4.106 CFU) in BALB/c mice, in a
model of asthma. Only the highest dose (4.106 CFU) caused a significant decrease in the number
of monocytes, lymphocytes and neutrophils in bronchoalveolar lavage fluid [62].
In oral administration, we distinguish the intra-gastric (IG) administration, in other words the
gavage (with a needle), from oral administration (PO) (probiotic mixed in water or food). These
two routes of exposure are principally used for the probiotic supplementation and whatever
the types of allergy study. Gavage allows giving a precise dose of bacteria, but it is constraining
because each animal must be handled individually leading to an additional stress in animals.
Administration of the probiotic strains in drinking water or food avoids these problems of
stress, but it raises the problem of their stability. Moreover, it does not allow knowing precisely
the amount of bacteria received per day per animal. Probiotic can also be given by intranasal
administration in models of asthma, or by epicutaneous exposure in models of atopic derma‐
titis. Intranasal administration allows a contact more extended with the probiotic, and
therefore a longer action. However, according to the protocols, an anesthesia is necessary
[107,108]. It could affect the lung antigen deposition by changing the breathing pattern and
airway reflexes in animal [109]. Pellaton et al have demonstrated that intranasal exposure is
more effective than gavage, with a lesser infiltration of eosinophils, in a model of asthma [106].
4.3. Window and frequency of probiotic administration
In the window of administration, we will consider the number of weeks of supplementation
as well as the number of administration per week. According to studies, the probiotic is
administered between 1 to 15 weeks, during 3 to 7 days per week.
The term “prevention” refers to an administration of the probiotic that starts prior to sensiti‐
zations and continues throughout the experiment. On the contrary, the term “management/
treatment” refers to an administration of the probiotic that starts after sensitizations until the
end of protocol.
In studies, probiotic is mainly tested for prevention and therefore administrated until two
weeks before the start of sensitizations. Meijerink et al began administration of probiotic by
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gavage 14 days prior to sensitizations [57]. Each of the three strains of Lactobacillus had a
different impact on allergy. The strain of L. plantarum WCFS1 have promoted allergic response
(increase of IgE, IgG1 and MCP-1), the strain of L. casei Shirota had no impact on allergy, while
the strain of L. salivarius HMI001 allowed the decrease of peanut-specific IgE and MCP-1. Yu
et al, in a model of asthma, have given a strain of L. rhamnosus Lcr35 in BALB/c mice, 7 days
before sensitizations. They observed a decrease in both bronchial hyperresponsiveness and
number of cells in bronchoalveolar fluid [110]. Some studies have administered the probiotic
in treatment, i.e. after the last sensitization, in models of food allergy and asthma, with a
positive impact of supplementation. Schiavi et al have demonstrated, in a model of shrimp
tropomyosin allergy, that the administration of VSL#3 during 20 days after the fourth sensi‐
tization allowed a decrease of clinical scoring and specific IgE, together with an induction of
IgA on C3H/HeJ mice [34]. Similar results have been found in studies of Zhang et al [35], and
Forsythe et al [111], with the administration of ImmuBalance™ in a model of food allergy, and
with the gavage of strain L. reuteri ATCC 23272 in a model of asthma, respectively.
This high heterogeneity in the different protocols of probiotic administration make difficult,
even impossible, comparisons between studies, and prevents establishment of an optimal
administration scheme of probiotic. Comparison between prevention and management
protocols shows that the window of administration plays a key role in the efficiency of
probiotic, with a better effect in prevention. Indeed, in a model of food allergy, Kim et al [33]
have showed, on C3H/HeJ mice sensitized to OVA, an improvement of allergic symptoms on
the tail associated with a decrease of specific IgE in prevention, more important than those
observed in treatment. Tanaka et al [42] in a model of atopic dermatitis and Yu et al [110] in a
model of asthma have obtained comparable results. On the contrary, Bickert et al revealed a
positive impact of probiotic, with an IP administration of Escherichia coli Nissle 1917 mixed
with OVA, at the same time of sensitizations [31]. In study of Huang et al, similar effects of
probiotics in prevention and treatment have been observed, suggesting that a long-term
supplementation was not necessary [45]. Zuercher et al have obtained more contrasted results.
They have observed that an oral administration of Lactococcus lactis NCC 2287 was effective in
the management of food allergy symptoms in sensitized BALB/c mice, with a decrease in
symptoms upon OVA challenge. However, this administration had no effect on the prevention
of sensitization, with similar levels of OVA-specific IgE and IgG1, and MCP-1 [75].
4.4. Age and sanitary status of animals
The age and the sanitary status of animals have also an influence. In study of Lyons et al, the
strain of Bifidobacterium AH1205 led to an increase of the percentage of CD4/CD25+cells in
spleen and Peyer’s patches in pups but not in adult mice. The strain of Bifidobacterium AH1206
had the same impact, but in both pups and adult mice. These two strains were then tested in
models of asthma and food allergy. Only the strain AH1206, which had an impact on pups
and adult mice, showed a positive impact on allergy, with a decrease in bronchoalveolar cell
number and OVA-specific IgE [112]. Similarly, depending on whether mice are germ-free or
conventional, the induction of CD4/CD25/Foxp3+cells in spleen was not the same, with a lower
induction in germ free, whatever the strain studied [112].
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5. Concluding remarks
At a time when probiotics seem promising products for the prevention and treatment of
allergy, fundamental and clinical studies failed the issuance of health claims and the imple‐
mentation of recommendations by expert committees. The use of animal models is an essential
step in the selection of strains of interest. However, such a use must be part of a rationalization
process taking into account the 3Rs (Reduce, Reuse and Recycle) and ethical rules. In vitro
models can bring the prior information on the behavior of the strains with respect to immu‐
nostimulary capacities. For instance, Foligne et al have discriminated pro- and anti-inflamma‐
tory strains in a model of human peripheral blood mononuclear cells according to their
cytokine profile [113]. Dendritic cells model can also allow selecting probiotic strains able to
prime monocyte-derived DCs to drive the development of Treg cells [114]. Based on this first
strain selection, animal models allow analyzing their mechanism of action. Indeed, probiotics
can act on various actors of immunity. They can improve the barrier integrity [115], induce
IgA secretion [28], and/or modulate T-helper balance, switching from Th2 to Th1 response
[116] or enhancing Treg activity [34]. However, one should consider carefully the choice of the
model and the design of probiotic administration to provide results which could be considered
predictive for benefits in human and support the design of clinical studies.
Strain Age Allergen Route Adjuvant Window References
BALB/c 6 wks BLG IP alum 1/wk, x1 wk [80]
BALB/c
male 3 wks BLG IP alum 1/wk, x3 wks [28]
BALB/c
female 6 wks OVA IP alum 1/2wks, x2 [100]
OVA-TCR
female 8 wks OVA IG / 4/wk, x2 wks [73]
C3H/HeOuJ
female 6 wks peanut extract IG CT
3/wk then 1/wk, x3
wks [57]
BALB/c 6 wks OVA IG CT 4/wk then 1/wk [75]
Swiss Albino 6-8 wks OVA IP alum 1/wk, x2 wks [116]
C3H/HeJ
female 8 wks
shrimp
tropomyosin IG CT 1/wk, x4 wks [34]
BALB/c
female 18-22g OVA IP SEB 3/wk, x1 wk [115]
C3H/HeJ
female 5 wks peanut extract IG CT 1/wk, x8 wks [35]
BALB/c male 7 wks OVA IP alum 1/wk, x2 wks [83]
C3H/HeJ 5 wks OVA IG CT 3/wk then 1/2wks, x2 [72]
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female
C3H/HeOuJ
female 3 wks whey protein IG CT 1/wk, x6 wks [74]
BALB/c 8 wks OVA IP CT 1/wk, x3 wks [112]
C57BL/6
female 8 wks peanut extract IG CT 1/wk, x4 wks [30]
C3H/HeJ
female 3 wks OVA IG CT 3/wk then 1/2wks, x2 [33]
Sprague-Dawley male 150-180g OVA IG and IP Freund 4/wk then 1/wk [44]
Brown-Norway female 3 wks OVA IG / 7/wk, x6 wks [45]
Brown-Norway female 3-4 wks peanut extract IG / 7/wk, x6 wks [43]
Yorkshire birth ovomucoid IP CT 1/wk, x3 wks [54]
Table 1. Protocols of sensitizations in food allergy
Strain Age Allergen Route Adjuvant Window References
GF BALB/c
female 8 wks Bet v 1 SC alum 1/2wks, x3 [60]
BALB/c female 5 wks cedar pollen SC / 5/2wks [70]
GF BALB/c birth Bet v 1 SC alum 1/2wks, x3 [59]
BALB/c
female 6 wks OVA IP alum 1/wk, x2 wks [91]
BALB/c
male 20-25g OVA IP alum 1/wk, x2 wks [104]
BALB/c
female 6-8 wks Der p SC Freund 1/wk, x2 wks [62]
BALB/c
female 6-10 wks
Bet v 1 + Phleum
pretense 1 and 5 IP alum 1/2wks, x3 [58]
BALB/c
male 5 wks OVA IP and IN alum
1/2wks (IP) then
3/wk, x4 wks
(IN)
[69]
BALB/c
female 3 wks cedar pollen SC / 4/wk then 1/wk [71]
BALB/c
female 6-8 wks OVA IP alum 1/2wks, x4 [82]
BALB/c
male 5-8 wks OVA IP alum 1/wk, x2 wks [81]
C57BL/6 female 6-8 wks OVA IP alum 1/2wks, x2 [31]
BALB/c 20-25g OVA IP alum 2/wk, x1 wk [111,117]
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male
C57BL/6 female 3-4 wks Der p2 EC / 1/2wks, x3 [32]
BALB/c 20-25g OVA IP CT 2/wk, x1 wk [112]
BALB/c - Der p1 IP alum 1/wk, x3 wks [61]
BALB/c
female 6 wks OVA IP alum 1/wk, x2 wks [110]
BALB/c
female 4 wks OVA IP alum 1/2wks, x2 [106]
BALB/c
female 8 wks OVA IP / 3/wk, x2 wks [118]
BALB/c
female 6-8 wks OVA IP alum 1/2wks, x2 [119]
BALB/c
female 8 wks Par j 1 IP alum 1/3wks, x2 [101]
Duroc x Landrace 3 wks Ascaris suum SC et IT alum
1/2wks, x3 (SC)
then 1/2wks, x2
(IT)
[55]
Table 2. Protocols of sensitizations in asthma
Strain Age Allergen Route Adjuvant Window References
NC/Nga - FITC EC dibutyl phtalate 1/wk, x3 wks [92]
NC/Nga male 6 wks DNCB EC / 2/wk, x2 wks [120]
NC/NgaTnd 8 wks / / / / [105]
SKH-1/fr
female 4 wks OVA EC / 1/3wks, x3 [90]
NC/Nga 6 wks Df EC SDS 1/wk, x5 wks [95]
NC/NgaTndCrlj
female 10 wks Df EC SDS 2/wk, x4 wks [88]
BALB/c female 8-10 wks OVA IP andEC alum
1/2wks, x2 then
7/2wk, x3 [94]
NC/NgaTnd 5 wks / / / / [42]
NC/Nga male 4 wks DF IP / 1/wk, x14 wks [121]
NC/Nga female 6 wks DNCB EC / 2/wk, x3 wks [89]
NC/Nga female birth / / / / [122]
NC/Nga 6 wks Df EC / 3/wk, x5 wks [66]
NC/Nga male 6 wks PCl EC / 1x [93]
Beagle birth Df EC / 3/wk, x1 wk [53]
Beagle birth Df EC / 2/wk, x12 wks [52]
Table 3. Protocols of sensitizations in atopic dermatitis
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Probiotic Route Window Dose Impact References
L. plantarum NRIC0380 IG 3/wk, x4 wks 200µg or2mg sensitization ↘ [80]
VSL#3 IG 7/wk, x5 wks 15.109 CFU clinicsensitization
↘
↘ [28]
L. casei YIT9029 (L1)
L. casei HY7201 (L2)
L. brevis HY7401 (L3)
L. plantarum HY20301 (L4)
IG 7/wk, x3 wks 2mg sensitization L1, L3, L4, ↗ L2 [100]
L. brevis HY7401 (LB)
L. casei Shirota YIT9029 (LC)
L. longum HY8001 (BL)
IG 4/wk, x2 wks 2mg clinicsensitization
↘ LB, LC, BL
↘ LB, LC, BL [73]
L. plantarum WCFS1 (LP)
L. salivarius HMI001 (LS)
L. casei Shirota (LC)
IG 3/wk, x6 wks 109 CFU sensitization ↗ LP, ↘ LS, LC [57]
L. lactis NCC2287 PO 7/wk, x1 (M)or 8 (P) wks
5.108
CFU/mL
clinic
sensitization
P, ↘ M
P, M [75]
Dahi PO 7/wk, x1,2 or3 wk(s) - sensitization ↘ [116]
VSL#3 IG 7/wk, x3 wks 7,5.108 CFU clinicsensitization
↘
↘ [34]
Bifidobacterium IG 7/wk, x1 wk 108 CFU/mL sensitization ↘ [115]
ImmuBalance™ PO 7/wk, x4 wks 0,5 or 1% clinicsensitization
↘
↘ [35]
L. pentosus S-PT84 PO 7/wk, x5 wks 0,075% sensitization ↘ [83]
B. bifidum BGN4 PO
7/wk, x7 wks
(P) or 7/wk,
x2 wks (M)
0,2% clinicsensitization
↘ P, M
↘ P, M
P > M
[72]
Immunofortis (IF)
B. breve M-16V (BB)
symbiotic (SY)
PO 7/wk, x10wks 2%
clinic
sensitization
↘ IF, BB, SY
↘ SY, IF, BB [74]
B. breve AH1205 (BB).
B. longum AH1206 (BL)
L. salivarius AH102 (LS)
IG 7/wk, x5 wks 2.109 CFU sensitization ↘ BL, BB, LS [112]
VSL#3 IG 7/wk, x3 wks 7,5.108 CFU clinic ↘ [30]
B. bifidum BGN4 (BB)
L. casei 911 (LC)
E. coli MC4100 (EC)
PO 7/wk, x7 wks 0,2% sensitization ↘ BB, LC, ECBB, LC > EC [33]
LGG
B. animalis MB5 IG 7/wk, x4 wks 10
9 CFU - [44]
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LGG + B. longum BB536 IG 7/wk, x2, 3 or10 wks 0,5.10
9 CFU sensitization ↘ [45]
L. casei Shirota IG 7/wk, x8 wks 109 CFU sensitization [43]
L. lactis MG1363 IG
7/wk, then
3/wk then
1/wk, x3 wks
109 CFU clinicsensitization ↘ [54]
Table 4. Protocols of probiotic administration in models of food allergy
Probiotic Route Window Dose Impact References
B. longum ssp. longum
CCM7952 IG
1x (parents
before coupling) 2.10
8 CFU sensitization ↘ [60]
E. faecalis FK-23 IG 7/wk, x3 wks 60mg infiltrationsensitization [70]
L. paracasei NCC2461 PO 7/wk, x4 wks 2.10
9
CFU/mL
clinic
sensitization ↘ [59]
L. rhamnosus Lcr35 IG 7/wk, x3 wks 10
9 CFU/
600µL infiltration ↘ [91]
E. faecalis FK-23 IG 7/wk, x4 wks 60mg infiltration ↘ [104]
L. gasseri A5 IG 7/wk, x4 wks 1,2 or 4.10
6
CFU sensitization [62]
L. paracasei NCC2461
B. longum NCC3001 IN
day of sensiti-
zation (M) or
3/wk, x2 wks (P)
5.108 CFU sensitization ↘ M, PNCC3010 > NCC2461 [58]
L. crispatus KT-11 (LC)
LGG (LG) PO 7/wk, x8 wks 5.10
7 CFU/g clinicsensitization
↘ LC, LG
↘ LC, LG [69]
E. faecalis FK-23 IG 7/wk, x3 wks 30mg sensitization [71]
L. salivarius PM-A0006 IG 7/wk, x8 wks
2,6 or
5,5.106 CFU,
or 3,6.107
CFU
infiltration
sensitization
↘
↘ [82]
B. breve M16V IG 7/wk, x2 wks 109 CFU infiltrationsensitization
↘
↘ [81]
E. coli Nissle 1917 IG
day of sensiti-
zation (M) or
7/wk, x4 wks (P)
108 CFU infiltrationsensitization
↘ M, P
↘ M, P [31]
L. reuteri ATCC23272 IG 7/wk, x1 wk 109 CFU infiltrationsensitization
↘
↘ [111,117]
L. casei Shirota IG 3/wk, x4 wks 109 CFU sensitization ↘ [32]
B. breve AH1205 (BB)
B. longum AH1206 (BL) IG 7/wk, x2 wks 2.10
9 CFU infiltration ↘ BL, BB, LS [112]
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L. salivarius AH102 (LS)
E. coli Nissle 1917 IN 3/wk, x2 wks 109 CFU sensitization ↘ [61]
L. rhamnosus Lcr35 IG 7/wk, x3 wks (P)or 1 wk (M) 10
9 CFU infiltrationsensitization
↘ P, M
↘ P, M [110]
L. paracasei NCC2461
(A)
L. plantarum NCC1107
(B)
IN or IG 7/wk, x1 wk 109 CFU infiltration ↘ A, BIN > IG [106]
LGG (LG)
B. lactis Bb-12 (BB) IG 4/wk, x8 wks 10
9 CFU infiltrationsensitization
↘ LG, BB
↘ LG, BB [118]
L. rhamnosus HN001 PO 7/wk, x7 wks 10.1010 CFU clinic ↘ [55]
Table 5. Protocols of probiotic administration in models of asthma
Probiotic Route Window Dose Impact References
Vitreoscilla filiformis CUT 1/wk, x4 wks 20% v/v clinicsensitization ↘ [92]
L. sakei probio 65 IG 7/wk, x2 wks 5.109 CFU/mL clinicsensitization
↘
↘ [120]
ImmuBalance™ PO 7/wk, x2 wks 1,8.108/g
clinic
infiltration
sensitization
↘
↘
↘
[105]
L. rhamnosus Lcr35 IG 7/wk, x8 wks 10
9 CFU/
600µL
clinic
infiltration
sensitization
↘
↘
↘
[90]
L. plantarum CJLP55 (A)
L. plantarum CJLP133 (B)
L. plantarum CJLP136 (C)
PO 7/wk, x8 wks 1010 CFU
clinic
infiltration
sensitization
↘ A, B, C
↘ A, B, C
↘ A, B, C
[95]
B. subtilis JCM20036 IG 6/wk, x4 wks 1,2.1017 CFU clinicinfiltration
↘
↘ [88]
E. coli Nissle 1917 PO 7/wk, x4 wks 10
7 or 108
CFU
clinic
infiltration
sensitization
↘
↘ [94]
L. rhamnosus
CGMCC1.3724 PO
7/wk, x12 wks
(P) or 7/wk, x7
wks (M)
5.108 CFU/mL clinicsensitization
↘ P, M
↘ P, M [42]
L. crispatus KT-11 (A)
L. crispatus KT-23 (B)
L. crispatus KT-25 (C)
PO 7/wk, x15 wks 1mg clinicsensitization
↘ A, B, C
↘ A, B, C [121]
B. subtilis KCTC1666 + L.
acidophilus KCTC3155 PO 7/wk, x3 wks 1 or 2%
clinic
sensitization
↘
2% > 1% [89]
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LGG PO 7/wk, x10 wks 4.104 CFU/g
clinic
infiltration
sensitization
↘
↘ [122]
L. johnsonii NCC533 IG 2 days 1,5.10
11
CFU/mL
clinic
sensitization ↘ [66]
L. paracasei KW3110 +
LGG PO 7/wk, x11 wks 0,03% or 0,3%
clinic
sensitization
↘
0,3% > 0,03% [93]
LGG Culturelle® IG 7/wk, x6 months 20.109 CFU - [53]
LGG IG 7/wk, x6 months clinic ↘ [52]
Impact of probiotic by comparison with control mice, in term of clinical score (clinic); markers of sensitization, i.e. aller‐
gen-specific and total IgE and IgG1 (sensitization); and infiltration of inflammatory cells, i.e. lymphocytes, neutrophils,
eosinophils and monocytes, in lung and/or bronchoalveolar fluid (infiltration).
↗ increase in symptoms or negative effect; ↘ decrease in symptoms or positive effect;→ no change in symptoms or no
effect
Table 6. Protocols of probiotic administration in models of atopic dermatitis
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